Globus Medical to acquire Nevro for $250 million
AUDUBON, Pa. - Globus Medical , Inc. (NYSE: NYSE:GMED), a prominent musculoskeletal solutions company with a market capitalization of $11.81 billion and an "GREAT" financial health rating according to ...
ndtvprofit1d
Swiggy Q3 Review: Quick Commerce Remains Pain Point As Competition Intensifies
UBS maintained a 'Buy' rating on Swiggy stock with a target price of Rs 510, while Macquarie maintained an 'Underperform' ...
Palantir Q4: Sell Now To Avoid Pain Later (Rating Downgrade)
Palantir’s Q4 revealed a 45% operating margin and 36% revenue growth, but its shares reflect over five years’ growth already.
The plague of souring small loans is back
The microfinance sector is experiencing significant stress, with rising delinquencies affecting banks and non-bank lenders. Seasonal factors and increased borrower indebtedness have prompted cautious ...
Weak demand weighs on Asian Paints Q3; analysts see more pain in near-term
Asian Paints' consolidated net profit attributable to the owners of the company declined 23.3 per cent year-on-year (Y-o-Y) ...
infectiousdiseaseadvisor.com2d
Journavx, a Nonopioid Oral Pain Medication, Gets FDA Approval
The Food and Drug Administration has approved Journavx (suzetrigine) for the treatment of moderate to severe acute pain in adults.
Ranking the five best and worst stadiums in the NFL based on their Yelp reviews
NFL stadiums are meant to enhance fan experience, but some are much better at it than others. Here are the five best and worst NFL stadiums per Yelp.
Science News6d
A new kind of non-opioid painkiller gets FDA approval
Patients seeking an opioid-free way to handle pain experienced in the short-term will soon have a new option.
Scientific American6d
What Is Journavx, the New Opioid-Free Painkiller from Vertex?
The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...
Karla Sofía Gascón Apologizes For Resurfaced Tweets—All The ‘Emilia Pérez’ Controversies, Explained
The film, which led this year’s Oscar nominations, has sparked controversy for its portrayal of cartel violence in Mexico and its transgender lead character.
BioSpace6d
FDA Approves Vertex’s Journavx as First New Pain Drug in Decades
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...
Buy Rating for Vertex Pharmaceuticals: FDA Approval of Journavx Boosts Market Potential and Stock Price Target
Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to ...